<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02565602</url>
  </required_header>
  <id_info>
    <org_study_id>2012/01000</org_study_id>
    <nct_id>NCT02565602</nct_id>
  </id_info>
  <brief_title>Comparison of Calcium Metabolism in Caucasian and Asian Postmenopausal Women of Chinese Descent and the Use of Strontium as a Qualitative Marker of Calcium Metabolism</brief_title>
  <official_title>A Comparative Study of Calcium Metabolism in Caucasian and Asian Postmenopausal Women of Chinese Descent and the Use of Strontium as a Qualitative Marker of Calcium Metabolism in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University, Singapore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to: 1) quantitatively assess parameters of bone calcium balance in healthy
      postmenopausal Asian women of Chinese descent; 2) assess possible ethnic differences in
      calcium metabolism by direct comparison of acquired data in Chinese postmenopausal women with
      those acquired earlier in Caucasian postmenopausal women using the same methodology; 3)
      assess differences in calcium and strontium metabolism in parallel to evaluate if strontium
      stable isotopes can be used for tracing bone calcium metabolism qualitatively
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will follow closely the protocol that was used previously by the PI at ETH Zurich
      to study calcium metabolism in healthy postmenopausal women. Calcium metabolism will be
      studied after a single oral administration of a calcium tracer (Ca-41) and by following the
      excretion of the tracer in urine over 6 months. Obtained data will be used to assess
      parameters of calcium metabolism (flux rates and sizes of body calcium compartments) by
      kinetic modelling. A strontium tracer (Sr-84) will be administered in parallel and its
      urinary excretion pattern compared to Ca-41 excretion to determine if strontium tracers can
      be used to assess calcium metabolism qualitatively. Subjects will be supplemented with Vit D
      throughout the study. Vit D supplementation will commence 1 month before isotope
      administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time changes in urinary tracer excretion (Ca-41 and Sr-84)</measure>
    <time_frame>6 months post dose</time_frame>
    <description>Urine samples collected from participants are analysed for calcium and strontium content as well as Ca-41 and Sr-84 excretion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Flux rates and relative compartment sizes (mineralized bone, exchangeable bone calcium, plasma calcium) of the study population</measure>
    <time_frame>6 months post dose</time_frame>
    <description>Flux rates (mg/day) and calcium distribution between compartments (% body calcium) will be obtained by compartmental modelling of urinary tracer data. Obtained data will be compared to a mirroring study conducted earlier in Caucasian postmenopausal women.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between flux rates and relative compartment sizes for calcium and strontium in each individual subject</measure>
    <time_frame>6 months post dose</time_frame>
    <description>Flux rates (mg/day), and calcium and strontium distribution between compartments (% body calcium and strontium ) will be obtained by compartmental modelling of urinary tracer data</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Calcium Metabolism</condition>
  <arm_group>
    <arm_group_label>Ca-41 &amp; Sr-84 (isotope tracers) &amp; vit D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dosages: 3.7 kBq (100 nCi) Ca-41, 5 mg of Sr-84 and 400IU of vitamin D (daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ca-41(isotope tracer)</intervention_name>
    <description>Ca-41 is given orally in the form of (Ca-41)Cl3 in citrate-buffered solution. Tracer will be used to determine parameters of calcium metabolism based on tracer excretion data.</description>
    <arm_group_label>Ca-41 &amp; Sr-84 (isotope tracers) &amp; vit D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sr-84 (isotope tracer)</intervention_name>
    <description>Sr-84 is given orally in the form of (Sr-84)Cl2 in aqueous solution.Tracer will be used to determine parameters of strontium metabolism based on tracer excretion data.</description>
    <arm_group_label>Ca-41 &amp; Sr-84 (isotope tracers) &amp; vit D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>One tablet daily (400IU per tablet)</description>
    <arm_group_label>Ca-41 &amp; Sr-84 (isotope tracers) &amp; vit D</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Last menstrual bleeding was at least 5 years ago.

          2. Between the ages of 50 and 75 years old.

          3. Both parents and 4 grandparents are/were of Chinese descent. It is not a necessity for
             the participant, participant's parents and grandparent's to be born and raised in
             Singapore to participate in this study.

          4. BMI above 16 and below 30

        Exclusion Criteria:

          1. Diagnosed with osteoporosis

          2. Presence of significant liver disease, malignancy (excluding myeloma in the study
             group), malabsorption syndrome, hypoparathyroidism, hyperparathyroidism, sarcoidosis
             or hyperthyroidism (from toxic multinodular goitre or Graves disease), Paget's disease
             osteosarcoma, acromegaly, Cushing's syndrome, hypopituitarism, diabetes mellitus or
             severe chronic obstructive pulmonary disease.

          3. Current smoking and an alcohol intake exceeding one standard drink per day

          4. Undergoing treatment with any of the following drugs (within the last 12 months) i)
             adrenocorticoid steroids (3 months or longer at anytime or &gt;10 days of treatment
             within the previous 12 months) ii) anticonvulsant therapy iii) pharmacological doses
             of thyroid hormone (causing decline of TSH below normal) iv) bisphosphonates v)
             calcitonin vi) synthetic parathyroid hormone vii) selective estrogen receptor
             modulators viii) strontium ranelate ix) estrogen therapy x ) chemotherapeutic agents
             xi) sodium fluoride (any history of treatment with fluoride) xii) medications known to
             affect calcium metabolism (diuretics, antacids, calcium channel blockers etc.).

          5. Presence of any other chronic illnesses.

          6. Any other significant medical, psychiatric and/or social issue as determined by the
             investigator that would compromise subject's safety and/or compliance with trial
             procedure.

          7. Any other clinically significant screening laboratory abnormality (as determined by
             the investigators).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Walczyk</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University, Singapore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lawrence Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Medicine Unit</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Cabrera WE, Schrooten I, De Broe ME, D'Haese PC. Strontium and bone. J Bone Miner Res. 1999 May;14(5):661-8. Review.</citation>
    <PMID>10320513</PMID>
  </reference>
  <reference>
    <citation>Denk E, Hillegonds D, Vogel J, Synal A, Geppert C, Wendt K, Fattinger K, Hennessy C, Berglund M, Hurrell RF, Walczyk T. Labeling the human skeleton with 41Ca to assess changes in bone calcium metabolism. Anal Bioanal Chem. 2006 Nov;386(6):1587-602. Epub 2006 Oct 11.</citation>
    <PMID>17033771</PMID>
  </reference>
  <reference>
    <citation>Denk E, Hillegonds D, Hurrell RF, Vogel J, Fattinger K, Häuselmann HJ, Kraenzlin M, Walczyk T. Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass. J Bone Miner Res. 2007 Oct;22(10):1518-25.</citation>
    <PMID>17576167</PMID>
  </reference>
  <reference>
    <citation>Lee WH, Wastney ME, Jackson GS, Martin BR, Weaver CM. Interpretation of 41Ca data using compartmental modeling in post-menopausal women. Anal Bioanal Chem. 2011 Feb;399(4):1613-22. doi: 10.1007/s00216-010-4454-5. Epub 2010 Dec 9.</citation>
    <PMID>21152905</PMID>
  </reference>
  <reference>
    <citation>Lin Y, Hillegonds DJ, Gertz ER, Van Loan MD, Vogel JS. Protocol for assessing bone health in humans by tracing long-lived 41Ca isotope in urine, serum, and saliva samples. Anal Biochem. 2004 Sep 1;332(1):193-5.</citation>
    <PMID>15301966</PMID>
  </reference>
  <reference>
    <citation>Suzuki T. Risk factors for osteoporosis in Asia. J Bone Miner Metab. 2001;19(3):133-41. Review.</citation>
    <PMID>11368297</PMID>
  </reference>
  <reference>
    <citation>Villegas R, Gao YT, Dai Q, Yang G, Cai H, Li H, Zheng W, Shu XO. Dietary calcium and magnesium intakes and the risk of type 2 diabetes: the Shanghai Women's Health Study. Am J Clin Nutr. 2009 Apr;89(4):1059-67. doi: 10.3945/ajcn.2008.27182. Epub 2009 Feb 18.</citation>
    <PMID>19225116</PMID>
  </reference>
  <reference>
    <citation>Wastney ME, Martin BR, Peacock M, Smith D, Jiang XY, Jackman LA, Weaver CM. Changes in calcium kinetics in adolescent girls induced by high calcium intake. J Clin Endocrinol Metab. 2000 Dec;85(12):4470-5.</citation>
    <PMID>11134095</PMID>
  </reference>
  <reference>
    <citation>Wu L, Martin BR, Braun MM, Wastney ME, McCabe GP, McCabe LD, DiMeglio LA, Peacock M, Weaver CM. Calcium requirements and metabolism in Chinese-American boys and girls. J Bone Miner Res. 2010 Aug;25(8):1842-9. doi: 10.1002/jbmr.76.</citation>
    <PMID>20205166</PMID>
  </reference>
  <reference>
    <citation>International Commission on Radiological Protection (1991) Biological aspects of radiological protection. Annals of the ICRP. 21, 11-25.</citation>
  </reference>
  <reference>
    <citation>International Commission on Radiological Protection (1994) Tables of dose coefficients. Annals of the ICRP. 24, 18-20.</citation>
  </reference>
  <reference>
    <citation>Schulze-König, T., Maden, C., Denk, E., Freeman, S. P. H. T., Stocker, M., Suter, M., Synal, A., Walczyk, T. (2010) Comparison of 41Ca analysis on 0.5 MV and 5 MV-AMS systems. Nuclear Instruments and Methods in Physics Research B. 268, 752-755.</citation>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2015</study_first_submitted>
  <study_first_submitted_qc>September 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2015</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National University, Singapore</investigator_affiliation>
    <investigator_full_name>Thomas Walczyk</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Calcium metabolism</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Postmenopausal women</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

